Law Offices of Thomas J. Lamb

  • About Firm
  • Practice Areas
  • Free Case Evaluation
  • Quick Contact Form
  • Frequently Asked Questions
  • Attorney Tom Lamb

Wegovy / Rybelsus / Ozempic DVT Blood Clots Side Effects Cases

February 26, 2024 By Law Offices of Thomas J. Lamb, P.A.

Wegovy, Rybelsus, and Ozempic DVT blood clots side effects have not received as much attention as adverse event reports that involve severe stomach conditions such as gastroparesis, gastric stasis, and stomach paralysis. Ozempic, Wegovy, and Rybelsus are three popular GLP-1 receptor agonists containing semaglutide that are increasingly used as … [Read more...]

Filed Under: Unsafe Drugs Tagged With: blood clots, Deep Vein Thrombosis (DVT), Ozempic, Rybelsus, semaglutide-containing drugs, Wegovy

Gastroparesis Cases Involving Ozempic, Rybelsus, Wegovy, and Trulicity as Weight-loss Drugs

February 13, 2024 By Law Offices of Thomas J. Lamb, P.A.

We are handling gastroparesis cases involving Ozempic, Rybelsus, Wegovy, and Trulicity as drug injury lawsuits filed against the responsible pharmaceutical companies. In this piece, we point out two medical journal articles that present a few gastroparesis cases involving the use of semaglutide (Ozempic, Rybelsus, Wegovy) or dulaglutide … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastroparesis, Ozempic, Rybelsus, semaglutide-containing drugs, Trulicity, Wegovy

Prolia Drug Label Change: Warning for Severe Hypocalcemia in Patients With Chronic Kidney Disease

January 23, 2024 By Law Offices of Thomas J. Lamb, P.A.

A January 2024 Prolia drug label change that added a “Black-Box” warning for the “new” Prolia hypocalcemia side effect was announced through this Drug Safety Communication “FDA adds Boxed Warning for increased risk of severe hypocalcemia in patients with advanced chronic kidney disease taking osteoporosis medicine Prolia (denosumab).” This … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Hypocalcemia, Prolia

Syfovre Safety Issues Raised In December 2023 JAMA Viewpoint Piece

January 5, 2024 By Law Offices of Thomas J. Lamb, P.A.

A December 2023 JAMA Ophthalmology Viewpoint piece about Syfovre safety issues was reported on in a December 7, 2023, Managed Healthcare Executive article, “Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint”: An independent panel of retinal specialists and statisticians should assess the clinical trial data for … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Syfovre

New Syfovre Warnings for Retinal Vascular Occlusion and Retinal Vasculitis

December 27, 2023 By Law Offices of Thomas J. Lamb, P.A.

A November 2023 label change added new Syfovre warnings for retinal vascular occlusion and retinal vasculitis cases associated with Syfovre injections. With these new Syfovre warnings, it now seems that the retinal vascular occlusion and retinal vasculitis cases associated with Syfovre use are due to the drug itself and not the injection kits, as … [Read more...]

Filed Under: Unsafe Drugs Tagged With: drug injury lawsuits, retinal vascular occlusion, retinal vasculitis, Syfovre

Syfovre Vision Side Effects Cases Reported at Ophthalmology Meeting

November 15, 2023 By Law Offices of Thomas J. Lamb, P.A.

A Syfovre vision side effects cases presentation was one of the most important at the 2023 Annual Meeting of the American Academy of Ophthalmology (AAO) in San Francisco in early November. William J. Johnson, M.D., of the Wolfe Clinic in Iowa, reported on Syfovre vision side effects cases ranging from hemorrhagic occlusive vasculitis-type … [Read more...]

Filed Under: Uncategorized, Unsafe Drugs Tagged With: blindness, eye inflammation, occlusive retinal vasculitis, Syfovre, vision loss

Wegovy, Rybelsus, and Ozempic Linked to Gastroparesis by Medical Study

October 26, 2023 By Law Offices of Thomas J. Lamb, P.A.

Patients who use drugs containing semaglutide are at an increased risk of gastroparesis, according to an October 2023 medical journal article about patients who used two different types of weight-loss drugs. The Novo Nordisk drugs Wegovy, Rybelsus, and Ozempic each have semaglutide as their active ingredient. Accordingly, Wegovy, Rybelsus, and … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastrointestinal-related adverse events, gastroparesis, Ozempic, Rybelsus, Wegovy

Retinal Vasculitis Cases Caused by Syfovre Injection Kits With a 19-gauge Filter Needle?

October 17, 2023 By Law Offices of Thomas J. Lamb, P.A.

In what seems to be the latest Syfovre safety update, in early October 2023 Apellis reported an increase in the number of Syfovre retinal vasculitis cases, but Apellis did not provide any significant new information regarding an “explanation” as to how certain Syfovre injection kits might have caused these adverse reaction events. EndPoints News … [Read more...]

Filed Under: Unsafe Drugs Tagged With: retinal vasculitis, Syfovre

Ozempic Gastrointestinal-related Adverse Events Cases Increasing

October 3, 2023 By Law Offices of Thomas J. Lamb, P.A.

The number of Ozempic gastrointestinal-related adverse events cases, including ileus cases, that have been reported to the FDA during the first 6 months of 2023 was covered in this September 28, 2023 article, “FDA Adds New Warning for Ileus to Semaglutide (Ozempic) Label”, published September 28, 2023, on the HCPLive® website: According to the US … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastric stasis, gastrointestinal-related adverse events, gastroparesis, ileus, Ozempic, Rybelsus, stomach paralysis, Wegovy

Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis

September 15, 2023 By Law Offices of Thomas J. Lamb, P.A.

In recent years we have seen an increasing number of adverse event reports for three Novo Nordisk semaglutide-containing drugs — Ozempic, Rybelsus, and Wegovy — that involve severe stomach conditions, including: Gastroparesis Gastric Stasis Stomach Paralysis The most common symptoms are nausea and vomiting, which can be severely … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gastric stasis, gastroparesis, Ozempic, Rybelsus, semaglutide-containing drugs, stomach paralysis, Wegovy

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

DrugInjuryLaw.com

DrugInjuryWatch.com

Asbestos-Mesothelioma.com

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Disclaimer and Copyright Notices
  • Sitemap

Copyright © 2025 · Law Offices of Thomas J. Lamb, P.A.